Kwality Pharmaceuticals (539997) Q3 25/26 earnings summary

Executive summary

• Achieved strong revenue and profit growth in Q3 and 9MFY26, driven by expansion in regulated and international markets and new product launches.

• Continued investments in R&D, capacity expansion, and regulatory compliance to support future growth.

• Board approved unaudited standalone and consolidated results for the quarter and nine months ended December 31, 2025.

Financial highlights

• Q3FY26 revenue rose 46.2% year-over-year to INR 123.4 crore; 9MFY26 revenue up 35.9% to INR 346 crore.

• Q3FY26 PAT increased 87.8% year-over-year to INR 16 crore; 9MFY26 PAT up 68% to INR 42 crore.

• EBITDA margin improved to 24.3% in Q3FY26 and 23% in 9MFY26.

• Standalone and consolidated Q3FY26 revenue: INR 123.44 crore; PAT: INR 16.01 crore and INR 16.00 crore; EPS: INR 15.43 and INR 15.42.

• Gross margin for FY25 at 56.2%, with PAT margin at 10.8%.

Outlook and guidance

• Targeting 35% revenue growth in FY26 and aiming for INR 650 crore revenue and 25% EBITDA margin by FY27.

• Q4FY26 revenue projected at INR 150 crore, with sequential EBITDA improvement expected.

• Targeting 30% CAGR beyond FY27, aiming for INR 1,000–1,100 crore revenue by FY29.

• Margins expected to improve by 300 bps by FY27, supported by specialty platform expansion and operational efficiencies.